Alnylam Pharmaceuticals — Third Quarter 2026 Earnings Summary

Alnylam Pharmaceuticals reported third-quarter 2026 global net product revenues of $1.292 billion, representing a 52% increase compared to the same period in 2025, driven primarily by a 59% growth in total TTR revenues to $1.150 billion. The company reiterated its full-year 2026 financial guidance and announced an expansion of the TRITON-CM Phase 3 study enrollment for nucresiran to 2,250 patients, with an expected launch by 2030. Additionally, positive Phase 1 data for brezosiran in Huntington's disease demonstrated robust target engagement, supporting plans to initiate a pivotal study in 2027. The company also advanced its pipeline with completed enrollment in the cAPPricorn-1 trial for mivelsiran and presented preclinical data for ALN-5288 targeting Alzheimer's disease.